Raxofelast, with the CAS number 128232-14-4, is a chemical compound that has garnered attention for its potential therapeutic applications, particularly in the context of inflammatory and autoimmune diseases. It is classified as a small molecule and is known for its ability to modulate certain biological pathways, which may contribute to its anti-inflammatory effects. The compound has been studied for its role in inhibiting specific enzymes or receptors involved in inflammatory processes, thereby potentially reducing tissue damage and improving clinical outcomes in affected individuals. Raxofelast's pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety profile. As research continues, the precise mechanisms of action and the full spectrum of its therapeutic potential are being explored, making it a subject of interest in pharmaceutical development. However, as with any investigational drug, comprehensive clinical trials are essential to establish its effectiveness and safety for human use.

Raxofelast

128232-14-4: Raxofelast, 5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid, 2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, (±)-, 2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, IRFI 016

2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-

Raxofelast (IRFI-016), a vitamin-like, hydrophilic antioxidant, mitigates ischemia-reperfusion in testis and may treat diabetic issues and atherosclerosis.

CAS 128232-14-4: Raxofelast

2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-

Ref: IN-DA000XVU

Raxofelast

Ref: TM-T34268

Raxofelast

Ref: 54-BUP12112